Autolus Therapeutics Rating A · Worker

Autolus Therapeutics is a healthcare company focused on the development of precisely targeted, controlled, and highly active autologous T-cell therapies. The company utilises advanced cell programming capabilities and chimeric antigen receptors to reprogram a patient's own T-cells, enabling them to recognise and destroy cancer cells.

The company operates its own proprietary viral vector and semi-automated cell manufacturing processes. Its clinical-stage programs target hematological and solid tumor indications, as well as autoimmune diseases.